the Dabur Group, has decided to divest its entire stake in Dabur
Pharma Ltd to Fresenius Kabi, a business segment of Fresenius SE, a
German multinational company with business in terests across the
global healthcare space at a price of Rs 76.50 per share.
A share purchase agreement to this effect has been signed in New Delhi
and the closing of the same is subject to requisite regulatory
approvals.
Dabur Pharma is the pharmaceutical business of the group and is
focused on the global oncology market.
Fresenius Kabi is a business segment of the healthcare group Fresenius
SE.
Explore your hobbies and interests. Click here to begin.
No comments:
Post a Comment